Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
PaperCitations, authors & open-access status
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 111 citations, 2022 year and closed oa status.
111
Citations
2022
Year
closed
OA Status